Ablation Devices: Technologies and Global Markets - Beckley, Bluefield & Lewisburg News, Weather, Sports

Ablation Devices: Technologies and Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Ablation Devices: Technologies and Global Markets

https://www.reportbuyer.com/product/2009158/Ablation-Devices-Technologies-and-Global-Markets.html

STUDY AND OBJECTIVE

• Define and identify key market segments and market structure in ablation technologies.
• Measure and estimate the global ablation market and its market segments, which include technologies, product categories, therapeutic markets and geographical segmentation.
• Identify key market dynamics and the factors impacting the global ablation market and its subsegments.
• To identify the trends, gaps and opportunities in each of the micromarkets.
• To focus exclusively on geographical segmentation. Analyze trends and opportunities in major regions: North America, Europe, Asia and the Rest of the World (ROW).
• To identify major stakeholders, product portfolio and recent developments, and draw a competitive landscape for the market leaders.

STUDY BACKGROUND

Ablation is a minimally invasive surgical technique that involves destruction or removal of dysfunctional tissues to treat life-threatening diseases such as cancers, atrial fibrillation, etc. It is also equally adopted for simple treatments in cosmetology, orthopedics, uterine fibroids, etc. There is an increase in prevalence and incident rates of lifestyle-oriented diseases and an increasing need to innovate minimally and noninvasive technologies to treat them. From 15% to 20% of ischemic strokes occur due to atrial fibrillation and about 12 million people in the U.S. are expected to suffer from this condition by 2050. Deaths due to cancers are reaching alarming rates across the globe. By the end of 2013, America is expected to have about 580,350 deaths due to cancer. With numerous technologies available to control and treat cardiovascular disorders and cancer, they still remain primary causes of death. Where conventional radiation therapies have been effective and been adopted due to high awareness levels, emerging technologies such as hydro-mechanical ablation, microwave and hydrothermal are increasing hopes among patients and healthcare service providers.
An increasingly aging population on one side and increasing healthcare expenditure on the other is becoming a major burden to governments across various countries. The regulatory and financial environment is getting significantly complex even in developed economies with governments focusing on cost-containment measures. The ablation procedure in this scenario is expected to be significantly preferred due to cost effectiveness (compared to conventional surgical techniques), shorter hospital stays, shorter recovery time and lesser risk of blood loss and infections.
A high level of economic instability, growing pockets of investment in developing economies and commercialization of next-generation technologies are compelling market participants to collaborate and leverage. The current scenario requires the market players to plan exclusive strategies after an in-depth understanding of geographical, regulatory, technology and other key market factors.

SCOPE OF THE REPORT

This research report presents an in-depth analysis of the global ablation market by technologies, product categories, therapeutic segments, key procedures and geographical markets. The report includes key technologies involved in thermal ablation techniques and nonthermal ablation techniques. The report discusses the role of supply chain members from manufacturers to surgeons. The report has an in-depth analysis of key companies operating in the global ablation market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and geographies such as the U.S., Europe and Japan.
The ablation devices market is mainly segmented into two classes: thermal and nonthermal technologies. Thermal technologies are further segmented into electrical, radiation, radio frequency, light, ultrasound, microwave and hydrothermal. The nonthermal technology market is segmented into cryotherapy and hydromechanical. The ablation devices technology market is further segmented on the basis of products offered for in-depth analysis of technology markets during the analysis period. The market study is detailed for technology based on procedures as well as its further implication on the therapeutic area. These two segmentations are also discussed in detailed for the given period. The market is segmented by geographical region into the Americas, Europe, Asia-Pacific and ROW. Companies profiled in this report include ConMed Corp., Varian Medical Systems Inc., Medtronic Inc., BSD Medical Corp., Olympus Corp., Urologix Inc., C.R. Bard Inc. and others.

INTENDED AUDIENCE

The INTENDED AUDIENCE includes:
• Ablation technologies and device manufacturers and potential entrants.
• Dealers, distributors and service providers of ablation devices.
• Robotics, life science and surgical companies.
• Healthcare-oriented software and analytics companies.
• Research institutes, associations and academicians.

SOURCE OF INFORMATION AND METHODOLOGY

The global ablation market was assessed and calculated through a bottom-up approach that involved identifying the market revenues of the micromarkets that make up the macromarkets. The following process was followed to ensure quality and consistency of estimates.
• In-depth primary and secondary research was conducted.
• Primary research included gathering intelligence from key market players. The participants of the interview include CEOs, key opinion leaders, product heads and directors.
• Secondary research not only included collation of data from freely available sources but also paid subscription from specialized industry magazines and websites.
• To best assure triangulation of market estimates, the derived values where again validated through primary research.
• Key factors considered during market estimations were price, volumes, incidence and prevalence rates, number of procedures, etc.

The geographical segmentation was assessed through various parameters such as the number of players in a particular region, incidence and prevalence rates, the extent of research activity occurring in that geography and future potential.

ANALYST CREDENTIALS

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, and life sciences and chemical markets. She has frequently delivered research services that contain strategic recommendations and business strategies to assist the market players in forming beneficial strategies. Yojana holds a B.Sc degree in Biotechnology and a MBA degree in Marketing.

REPORT HIGHLIGHTS

The global market for ablation devices reached nearly 8.1 billion in 2012. This market is expected to grow to $8.8 billion in 2013 and $15.1 billion in 2018 with a compound annual growth rate (CAGR) of 11.3% for the five-year period, 2013 to 2018.

This report provides:
• An overview of the global market for ablation devices
• Analyses of global market trends, with data from 2012, estiamtes for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• A breakdown of the market into segments such as types of technology, products, major market players, application, geography, and factors influencing demand
• A look at factors inhibiting market growth such as pricing, reimbursement policies, and stringent regulatory impositions
• Comprehensive company profiles of major players

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY AND OBJECTIVE 2
STUDY BACKGROUND 2
SCOPE OF THE REPORT 3
INTENDED AUDIENCE 3
SOURCE OF INFORMATION AND METHODOLOGY 3
ANALYST CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 5

CHAPTER 2 EXECUTIVE SUMMARY 7

SUMMARY TABLE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICAL
REGION, 2012-2018 ($ MILLIONS) 8

CHAPTER 3 ABLATION MARKET OVERVIEW 11

ABLATION DEVICES: TECHNOLOGY TRENDS AND INNOVATIONS 11
TYPES OF CONVENTIONAL SURGICAL PROCEDURES AND DRAWBACKS 13
HEART SURGERY 13
PLASTIC SURGERY 14
BRAIN SURGERY 14
CANCER SURGERY 15
ORTHOPEDIC SURGERY 15
GOVERNMENT REGULATIONS, MEDICAL ASSOCIATIONS, FOOD AND DRUG
ADMINISTRATION, AND INTERNATIONAL REGULATORY AGENCIES 16
TABLE 1 DEVICES THAT ARE NOT YET APPROVED FOR THE TREATMENT OF ATRIAL
FIBRILLATION 17
INDUSTRY STRUCTURE AND SUPPLY CHAIN PROCESS 18
ROLE OF MANUFACTURERS 18
ROLE OF DISTRIBUTORS 19
ROLE OF RESEARCH INSTITUTES AND CONSULTANTS 19
ROLE OF GOVERNMENTS 20
ROLE OF HOSPITALS AND SURGEONS 20
DEMOGRAPHICS, INCIDENCE AND PREVALENCE RATES AND OTHER
PARAMETERS INFLUENCING MARKET GROWTH 21
INCIDENCES AND PREVALENCE RELATING TO CANCERS 21
TABLE 2 CANCER DEMOGRAPHICS IN THE U.S., 2013 (ESTIMATED) 21
FIGURE 1 DEATHS DUE TO PROSTATE CANCER IN THE U.K., 2011 (%) 22
INCIDENCES AND PREVALENCE RELATING TO CARDIOVASCULAR DISEASES 23
TABLE 3 CARDIOVASCULAR DEMOGRAPHICS IN THE U.S. BY AGE, 2010 (%) 23
TABLE 4 EUROPEAN UNION STATISTICS OF CARDIOVASCULAR DISEASES AND
CIRCULATORY DISEASES, 2010 24
FIGURE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN ADULTS IN THE U.S.
AGE GROUP 45-64 YEARS, 2000 AND 2010 (%) 24
INCIDENCES AND PREVALENCE RELATING TO OPHTHALMOLOGY 25
TABLE 5 VISUAL IMPAIRMENT STATISTICS U.S., 2000 AND 2010 25
FIGURE 3 CAUSES OF VISUAL IMPAIRMENT, 2010 (%) 25
FIGURE 4 VISUAL IMPAIRMENT PER MILLION, 2010 (THOUSANDS) 26
FDA GUIDELINES FOR SELECTED PRODUCTS 27
TABLE 6 FDA GUIDELINES FOR SELECTED PRODUCTS, 2001–2013 28
REIMBURSEMENT SCENARIO 29
CODING CHANGES FOR CARDIOLOGY 30
Ablation Codes 30
TABLE 7 ABLATION CODES 30
TABLE 8 PHYSICIAN FEE SCHEDULE CODES 31
Comparison of 2012 and 2013 Codes 32
Case Study I 32
TABLE 9 ATRIAL FIBRILLATION ABLATION, PULMONARY VEIN ISOLATION 32
Case Study II 33
TABLE 10 DIAGNOSTICS OF ELECTROPHYSIOLOGY STUDY 33
MARKET DYNAMICS 34
TECHNOLOGICAL DEVELOPMENTS 34
HIGHER RISK OF CHRONIC ILLNESSES 34
FIGURE 5 WORLD PROJECTED MORTALITY TRENDS DUE TO CARDIOVASCULAR
DISEASES, 2008, 2015, 2030 (%) 34
FIGURE 6 U.S. CANCER DEMOGRAPHICS BY AGE AND GENDER, 2012 35
ABLATION THERAPY REQUIRES LESS TIME 36
LESS DAMAGE AND BLOOD LOSS 36
RESTRAINTS FOR THE GLOBAL ABLATION DEVICES MARKET 37
PRESSURE FROM REGULATORY AGENCIES 37
INSURANCE SETTLEMENT ISSUES 37
OPPORTUNITIES AND CHALLENGES FOR THE ABLATION DEVICES MARKET 38
GROWING MARKETS IN EMERGING ECONOMIES 38
NEED TO ENHANCE AWARENESS LEVELS 38

CHAPTER 4 ABLATION MARKET ANALYSIS BY TECHNOLOGIES 41

TABLE 11 GLOBAL MARKET FOR ABLATION DEVICES BY TECHNOLOGY, THROUGH
2018 ($ MILLIONS) 41
THERMAL TECHNOLOGY MARKET 41
TABLE 12 GLOBAL MARKET FOR THERMAL ABLATION DEVICES BY TECHNOLOGY,
THROUGH 2018 ($ MILLIONS) 42
ELECTRICAL ABLATION THERAPY 42
TABLE 13 GLOBAL MARKET FOR ELECTRICAL ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 42
RADIATION TECHNOLOGY 43
TABLE 14 GLOBAL MARKET FOR RADIATION ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 44
Types of Radiation Ablation Techniques 45
Intensity Modulated Radiation Therapy (IMRT) 45
Image-Guided Radiation Therapy (IGRT) 45
Helical Tomography 45
Particle Therapy 46
Stereotactic Radiotherapy 46
Brachytherapy 46
RADIO FREQUENCY (RFID) TECHNOLOGY 47
TABLE 15 GLOBAL MARKET FOR RADIO FREQUENCY ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 47
Uses of RFA 47
The Key Applications of RFA 48
Specific Application of RFID in Therapeutic Segments 48
Treatment of Liver Cancer 48
Treatment of Kidney Cancer 48
Treatment of Lung Cancer 48
Arrhythmias 49
Arthritis Pain 49
Treatment of Varicose Veins 49
LIGHT 49
TABLE 16 GLOBAL MARKET FOR LIGHT/LASER ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 50
ULTRASOUND 51
TABLE 17 GLOBAL MARKET FOR ULTRASOUND ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 51
TABLE 18 HIFU STUDIES IN KIDNEY TISSUES IN SPECIFIED COUNTRIES 52
HIFU in Prostate Cancer 52
HIFU in Primary and Secondary Liver Cancers 53
HIFU in Pancreatic Cancer 53
HIFU in Bladder Cancer 53
MICROWAVE 53
TABLE 19 GLOBAL MARKET FOR MICROWAVE ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54
HYDROTHERMAL 54
TABLE 20 GLOBAL MARKET FOR HYDROTHERMAL ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54
NONTHERMAL ABLATION TECHNOLOGY 55
TABLE 21 GLOBAL MARKET FOR NONTHERMAL ABLATION TECHNOLOGY, THROUGH
2018 ($ MILLIONS) 56
CRYOABLATION 56
TABLE 22 GLOBAL MARKET FOR CRYOABLATION TECHNOLOGY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 57
HYDROMECHANICAL 57
TABLE 23 GLOBAL MARKET FOR HYDROMECHANICAL TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 58

CHAPTER 5 ABLATION MARKET ANALYSIS BY PRODUCTS 60

ELECTRICAL 60
TABLE 24 GLOBAL MARKET FOR ELECTRICAL ABLATOR BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 60
ELECTRICAL ABLATORS 60
TABLE 25 GLOBAL MARKET FOR ELECTRICAL ABLATOR REVENUE BY PRODUCT,
THROUGH 2018 ($ MILLIONS) 61
Argon Plasma/Beam Coagulator 61
Irreversible Electroporation 61
ELECTRONIC BRACHYTHERAPY 62
RADIATION 62
TABLE 26 GLOBAL MARKET FOR RADIATION PRODUCTS BY REVENUE, THROUGH
2018 ($ MILLIONS) 62
BRACHYTHERAPY 62
TABLE 27 GLOBAL MARKET FOR BRACHYTHERAPY ABLATOR BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 63
High-Dose-Rate (HDR) Brachytherapy 63
TABLE 28 GLOBAL MARKET FOR HIGH-DOSE-RATE BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 63
Pulsed-Dose-Rate Brachytherapy 64
TABLE 29 GLOBAL MARKET FOR PULSE-DOSE-RATE BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 64
Permanent Seed Brachytherapy or Low-Dose-Rate (LDR)
Brachytherapy 64
TABLE 30 GLOBAL MARKET FOR PERMANENT SEED BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 65
STEREOTACTIC RADIOSURGERY AND STEREOTACTIC RADIOTHERAPY 65
TABLE 31 GLOBAL MARKET FOR STEREOTACTIC RADIOSURGERY (SRS) AND
STEREOTACTIC RADIOTHERAPY (SRT) MARKET REVENUE BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS)
66
IMAGE-GUIDED RADIATION THERAPY (IGRT) 66
TABLE 32 GLOBAL MARKET FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67
INTENSITY-MODULATED RADIATION THERAPY (IMRT) 67
TABLE 33 GLOBAL MARKET FOR INTENSITY-MODULATED RADIATION THERAPY
(IMRT) BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67
STEREOTACTIC BODY RADIATION THERAPY (SBRT) 68
TABLE 34 GLOBAL MARKET FOR STEREOTACTIC BODY RADIATION THERAPY (SBRT)
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 68
PROTON BEAM THERAPY 68
TABLE 35 GLOBAL MARKET FOR PROTON BEAM THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 69
RADIO FREQUENCY 69
TABLE 36 GLOBAL MARKET FOR RADIO FREQUENCY ABLATOR MARKET BY
PRODUCT, THROUGH 2018 ($ MILLIONS) 69
TEMPERATURE-CONTROLLED RADIO FREQUENCY ABLATION DEVICES 70
TABLE 37 GLOBAL MARKET FOR TEMPERATURE-CONTROLLED RADIO FREQUENCY
ABLATION DEVICES BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 70
FLUID-COOLED RF ABLATION 70
TABLE 38 GLOBAL MARKET FOR FLUID COOLED RF ABLATION DEVICES BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71
THE ROBOTIC CATHETER MANIPULATION SYSTEM 71
TABLE 39 GLOBAL MARKET FOR CATHETER MANIPULATION SYSTEM DEVICES BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71
LIGHT/LASER 72
TABLE 40 GLOBAL MARKET FOR LIGHT/LASER BY PRODUCT, THROUGH 2018 ($
MILLIONS) 72
COLD LASER 72
TABLE 41 GLOBAL MARKET FOR COLD LASER DEVICES BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 73
EXCIMER LASER 73
TABLE 42 GLOBAL MARKET FOR EXCIMER LASER DEVICES BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 73
ULTRASOUND 74
TABLE 43 GLOBAL MARKET FOR ULTRASOUND ABLATION PRODUCTS, THROUGH
2018 ($ MILLIONS) 74
HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 74
TABLE 44 GLOBAL MARKET FOR HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 75
MAGNETIC RESONANCE-GUIDED ULTRASOUND (MRGUS) 75
TABLE 45 GLOBAL MARKET FOR MAGNETIC RESONANCE–GUIDED ULTRASOUND
(MRGUS) ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76
ULTRASONIC SURGICAL SYSTEMS 76
TABLE 46 GLOBAL MARKET FOR ULTRASONIC SURGICAL SYSTEMS BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76
EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY 77
TABLE 47 GLOBAL MARKET FOR EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY
PRODUCT BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 77
MICROWAVE ABLATION 77
TABLE 48 GLOBAL MARKET FOR MICROWAVE ABLATION PRODUCT BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 78
HYDROTHERMAL ABLATION/ ENDOMETRIAL HYDROTHERMAL BALLOON
ABLATION DEVICES 78
TABLE 49 GLOBAL MARKET FOR HYDROTHERMAL ABLATION PRODUCT BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 79
CRYOABLATION 79
TABLE 50 GLOBAL MARKET FOR CRYOABLATION PRODUCTS BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 80
TISSUE CONTACT PROBE 80
TISSUE SPRAY PROBE 80
EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 81
ADVANCEMENT IN ROBOTIC ABLATION TECHNIQUE 81
VARIOUS PROCEDURES THAT ARE ROBOTIC IN NATURE 82
STEERABLE CATHETERS 82
HEARTLANDER 82
ROBOTIC RADIOTHERAPY 82
ROBOTIC ABLATION FOR ARRHYTHMIA 82
LEADING ROBOTIC SYSTEMS USED IN CATHETER ABLATION 83
Niobe (Stereotaxis) 83
Sensei (Hansen Medical) 83
Amigo (Catheter Robotics) 83
Artis Zeego (Siemens) 83
TABLE 51 GLOBAL MARKET FOR ROBOTIC ABLATION BY PRODUCT, THROUGH 2018
($ MILLIONS) 83

CHAPTER 6 ABLATION MARKET ANALYSIS BY PROCEDURES 86

TABLE 52 GLOBAL ABLATION MARKET BY PROCEDURE, THROUGH 2018 ($
MILLIONS) 86
AESTHETICS-SKIN REJUVENATION AND TIGHTENING 86
TABLE 53 GLOBAL MARKET FOR AESTHETICS-SKIN REJUVENATION AND
TIGHTENING BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 87
LASER SKIN REJUVENATION 87
ILLUSTRATION: VICTORIAN COSMETIC INSTITUTE'S CASE STUDIES 87
RADIO FREQUENCY (RF) FOR FACIAL SKIN REJUVENATION 88
AESTHETICS-BODY SCULPTING, FAT REDUCTION AND REDUCTION IN THE
APPEARANCE OF CELLULITE 89
TABLE 54 GLOBAL MARKET FOR AESTHETICS-BODY SCULPTING, FAT REDUCTION
AND REDUCTION IN THE APPEARANCE OF CELLULITE ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
89
HIFU FOR FAT REDUCTION 89
ILLUSTRATION: ELSEVIER HEALTH JOURNAL 90
VACUUM MASSAGE FOR CELLULITE REDUCTION 90
BENIGN PROSTATIC HYPERPLASIA ABLATION 91
TABLE 55 GLOBAL MARKET FOR BENIGN PROSTATIC HYPERPLASIA ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 91
GREENLIGHT LASER PROCEDURE FOR BENIGN PROSTATE HYPERPLASIA 91
ILLUSTRATION: EUROPEAN UROLOGY CENTER 91
THERMOTHERAPY FOR BENIGN PROSTATE HYPERPLASIA 92
TRANSURETHRAL NEEDLE ABLATION 92
TABLE 56 GLOBAL MARKET FOR TRANSURETHRAL NEEDLE ABLATION PROCEDURE
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 93
ILLUSTRATION: DIVISION OF UROLOGY, JOHANNESBURG HOSPITAL, SOUTH
AFRICA 93
LASER- AND OTHER ENERGY-BASED THERAPIES/HOLMIUM LASER
ABLATION/ENUCLEATION OF THE PROSTATE 94
HOLMIUM LASER ENUCLEATION OF PROSTATE CANCER HLEOP 94
TABLE 57 GLOBAL MARKET FOR LASER- AND OTHER ENERGY-BASED ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 94
ILLUSTRATION 94
ABLATION FOR ATRIAL FIBRILLATION 95
TABLE 58 GLOBAL MARKET FOR ATRIAL FIBRILLATION ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 95
PAROXYSMAL ATRIAL FIBRILLATION 96
PERSISTENT ATRIAL FIBRILLATION 96
CANCER/TUMOR ABLATION 96
TABLE 59 GLOBAL MARKET FOR CANCER ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 97
MENORRHAGIA/ENDOMETRIAL ABLATION 97
TABLE 60 GLOBAL MARKET FOR MENORRHAGIA/ENDOMETRIAL ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 98
HEATED BALLOON PROCEDURE 98
SPINAL DECOMPRESSION AND DENERVATION 99
TABLE 61 GLOBAL MARKET FOR SPINAL DECOMPRESSION AND DENERVATION
ABLATION PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 99
DIAGNOSTIC MEDIAL BRANCH BLOCK (MBB) 99
RADIO FREQUENCY ABLATION (RFA) FOR BACK PAIN 100
STRESS URINARY INCONTINENCE 100
TABLE 62 GLOBAL MARKET FOR STRESS URINARY INCONTINENCE ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 101
TRANSURETHRAL RADIO FREQUENCY COLLAGEN DENATURATION 101
VARICOSE VEIN ABLATION 101
TABLE 63 GLOBAL MARKET FOR VARICOSE VEIN ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 102
RADIO FREQUENCY ABLATION (RFA) FOR VARICOSE VEINS 102
UTERINE FIBROIDS 103
TABLE 64 GLOBAL MARKET FOR UTERINE FIBROIDS ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 103
HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) FOR UTERINE FIBROIDS 103
OTHER PROCEDURES 104
ELASA EYE SURGERY 104

CHAPTER 7 ABLATION MARKET ANALYSIS BY THERAPEUTICS 106

TABLE 65 GLOBAL MARKET FOR ABLATION THERAPEUTICS, THROUGH 2018 ($
MILLIONS) 106
CANCER/ONCOLOGY 106
TABLE 66 GLOBAL MARKET FOR CANCER ABLATION THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 107
CARDIOVASCULAR 107
TABLE 67 GLOBAL MARKET FOR CARDIOVASCULAR ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 108
OPHTHALMOLOGY 109
TABLE 68 GLOBAL MARKET FOR OPHTHALMOLOGY ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 109
COSMETOLOGY 110
GYNECOLOGY 111
TABLE 69 GLOBAL MARKET FOR GYNECOLOGY ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 112
UROLOGY 112
TABLE 70 GLOBAL MARKET FOR UROLOGY ABLATION THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 113
CRYOABLATION FOR PROSTATE CANCER 113
ORTHOPEDICS 114
TABLE 71 GLOBAL MARKET FOR ORTHOPEDICS THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 114
RADIO FREQUENCY ABLATION (RFA) FOR ORTHOPEDIC TREATMENT 114
PAIN MANAGEMENT 115
CRYOABLATION IN PAIN MANAGEMENT 115
OTHERS 116
TABLE 72 GLOBAL MARKET FOR OTHER THERAPY BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 116
COBLATION FOR TONSILLITIS 116
PORT-WINE STAINS 117
ABLATION OF PORT-WINE STAINS 117

CHAPTER 8 COMPETITIVE LANDSCAPE 119

FIGURE 7 KEY COMPETITIVE STRATEGIES*, 2010-2013 (%) 119
PRODUCT LAUNCH 120
FIGURE 8 PRODUCT LAUNCH BY COMPANY*, 2010–2013 (%) 121
TABLE 73 LIST OF KEY PRODUCT LAUNCHES ANNOUNCED, 2010-2013 122
MERGERS AND ACQUISITIONS STRATEGY 124
FIGURE 9 MERGERS AND ACQUISITIONS BY COMPANIES*, 2010-2013 (%) 124
TABLE 74 MERGERS AND ACQUISITIONS STRATEGIES BY COMPANIES, 2010-2013 126
PARTNERSHIP AND COLLABORATION STRATEGY 127
FIGURE 10 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES*,
2010-2013 127
TABLE 75 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES,
2010-2012 129
APPROVALS AND OTHER STRATEGIES 130
FIGURE 11 APPROVALS AND OTHER STRATEGIES BY COMPANIES*, 2010-2013 (%) 131
TABLE 76 LIST OF APPROVALS AND OTHER STRATEGIES ANNOUNCED, 2010–2013 132

CHAPTER 9 GEOGRAPHICAL ANALYSIS 136

NORTH AMERICA 136
TABLE 77 ABLATION MARKET ESTIMATION FOR NORTH AMERICA, THROUGH 2018
($ MILLIONS) 136
EUROPE 137
TABLE 78 ABLATION MARKET ESTIMATION FOR EUROPE, THROUGH 2018 ($
MILLIONS) 137
ASIA PACIFIC 138
TABLE 79 ABLATION MARKET ESTIMATION FOR ASIA PACIFIC, THROUGH 2018 ($
MILLIONS) 138
REST OF WORLD (ROW) 139
TABLE 80 ABLATION MARKET ESTIMATION FOR ROW, THROUGH 2018 ($ MILLIONS) 140

CHAPTER 10 PATENT ANALYSIS 142

FIGURE 12 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE AND JAPAN,
2008-2013 (%) 142
THE U.S. PATENT ANALYSIS BY APPLICATION 142
FIGURE 13 U.S. PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 143
U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS 144
FIGURE 14 U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 144
EUROPE PATENT ANALYSIS BY TECHNOLOGY 145
FIGURE 15 EUROPE PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 145
EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS 146
FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 146
JAPAN PATENT ANALYSIS BY TECHNOLOGY 147
FIGURE 17 JAPAN PATENT ANALYSIS BY TECHNOLOGY, 2008–2013 (%) 147
JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS 148
FIGURE 18 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 148

CHAPTER 11 COMPANY PROFILES 150

ACCURAY INC 150
ACCURAY PRODUCT PORTFOLIO 150
TABLE 81 ACCURAY RECENT DEVELOPMENTS, 2010-2012 151
TABLE 82 ACCURAY FINANCIALS, 2010-2012 151
ALCON LABORATORIES INC. 151
ABLATION PRODUCT PORTFOLIO 152
TABLE 83 ALCON RECENT DEVELOPMENT, 2012 152
TABLE 84 ALCON FINANCIALS, 2010–2012 152
ANGIODYNAMICS INC. 153
ABLATION PRODUCT PORTFOLIO 153
TABLE 85 ANGIODYNAMICS RECENT DEVELOPMENTS, 2010-2012 154
TABLE 86 ANGIODYNAMICS FINANCIALS, 2010-2012 154
ARTHROCARE CORPORATION 155
ABLATION PRODUCT PORTFOLIO 155
TABLE 87 ARTHROCARE RECENT DEVELOPMENTS, 2010 156
TABLE 88 ARTHROCARE CORPORATION FINANCIALS, 2010-2012 156
ATRICURE INC. 156
ABLATION PRODUCT PORTFOLIO 157
TABLE 89 ATRICURE RECENT DEVELOPMENTS, 2010-2011 157
TABLE 90 ATRICURE FINANCIALS, 2010-2012 158
BIOSENSE WEBSTER 158
ABLATION PRODUCT PORTFOLIO 158
TABLE 91 BIOSENSE WEBSTER RECENT DEVELOPMENTS, 2010-2012 159
TABLE 92 BIOSENSE WEBSTER FINANCIALS, 2010-2012 159
BOSTON SCIENTIFIC CORPORATION 160
ABLATION PRODUCT PORTFOLIO 160
TABLE 93 BOSTON SCIENTIFIC CORPORATION RECENT DEVELOPMENTS, 2010-2012 161
TABLE 94 BOSTON SCIENTIFIC CORPORATION FINANCIALS, 2010-2012 161
BSD MEDICAL CORPORATION 161
ABLATION PRODUCT PORTFOLIO 162
TABLE 95 BSD MEDICALS RECENT DEVELOPMENTS, 2010-2012 162
TABLE 96 BSD MEDICALS FINANCIALS, 2010-2012 163
C.R. BARD INC. 163
ABLATION PRODUCT PORTFOLIO 163
TABLE 97 C.R. BARD RECENT DEVELOPMENTS, 2011-2012 164
TABLE 98 C.R. BARD FINANCIALS, 2010-2012 164
CONMED CORPORATION 164
ABLATION PRODUCT PORTFOLIO 165
TABLE 99 CONMED RECENT DEVELOPMENTS, 2010 165
TABLE 100 CONMED FINANCIALS, 2010-2012 166
COVIDIEN 166
ABLATION PRODUCT PORTFOLIO 166
TABLE 101 COVIDIEN RECENT DEVELOPMENTS, 2011-2013 167
TABLE 102 COVIDIEN FINANCIALS, 2010-2012 168
ELEKTA AB 168
ABLATION PRODUCT PORTFOLIO 168
TABLE 103 ELEKTA AB RECENT DEVELOPMENTS, 2010–2013 169
TABLE 104 ELEKTA AB FINANCIALS, 2010-2012 170
ENDOSENSE SA 170
ABLATION PRODUCT PORTFOLIO 170
TABLE 105 ENDOSENSE RECENT DEVELOPMENTS (BEFORE ACQUISITION),
2010-2011 171
GALIL MEDICAL LTD. 171
ABLATION PRODUCT PORTFOLIO 171
TABLE 106 GALIL MEDICAL LTD RECENT DEVELOPMENTS, 2011-2012 172
MEDTRONIC INC 172
ABLATION PRODUCT PORTFOLIO 172
TABLE 107 MEDTRONIC RECENT DEVELOPMENTS, 2010-2013 173
TABLE 108 MEDTRONIC FINANCIALS, 2010-2012 174
MISONIX INC. 174
ABLATION PRODUCT PORTFOLIO 174
TABLE 109 MISONIX INC RECENT DEVELOPMENTS, 2010-2012 175
TABLE 110 MISONIX FINANCIALS, 2010-2012 176
OLYMPUS CORPORATION 176
ABLATION PRODUCT PORTFOLIO 176
TABLE 111 OLYMPUS RECENT DEVELOPMENTS, 2010-2012 177
TABLE 112 OLYMPUS FINANCIALS, 2010-2012 177
ST. JUDE MEDICAL INC. 177
ABLATION PRODUCT PORTFOLIO 178
TABLE 113 ST. JUDE MEDICAL RECENT DEVELOPMENTS, 2010–2013 178
TABLE 114 ST. JUDE MEDICAL FINANCIALS, 2010-2012 179
UROLOGIX INC. 179
ABLATION PRODUCT PORTFOLIO 179
TABLE 115 UROLOGIX RECENT DEVELOPMENTS, 2011-2012 180
TABLE 116 UROLOGIX FINANCIALS, 2010-2012 180
VARIAN MEDICAL SYSTEMS INC. 180
ABLATION PRODUCT PORTFOLIO 181
TABLE 117 VARIAN MEDICAL SYSTEMS RECENT DEVELOPMENTS, 2010-2012 181
TABLE 118 VARIAN MEDICAL SYSTEMS INC, 2010-2012 182

CHAPTER 12 APPENDIX 184

LIST OF U.S. PATENTS 184
TABLE 119 LIST OF PATENTS: UNITED STATES, 2008-2013 184
LIST OF PATENTS: EUROPE 188
TABLE 120 LIST OF PATENTS: EUROPE, 2008-2013 188
LIST OF PATENTS: JAPAN 194
TABLE 121 LIST OF PATENTS: JAPAN, 2008-2013 194

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 8
TABLE 1 DEVICES THAT ARE NOT YET APPROVED FOR THE TREATMENT OF ATRIAL
FIBRILLATION 17
TABLE 2 CANCER DEMOGRAPHICS IN THE U.S., 2013 (ESTIMATED) 21
TABLE 3 CARDIOVASCULAR DEMOGRAPHICS IN THE U.S. BY AGE, 2010 (%) 23
TABLE 4 EUROPEAN UNION STATISTICS OF CARDIOVASCULAR DISEASES AND
CIRCULATORY DISEASES, 2010 24
TABLE 5 VISUAL IMPAIRMENT STATISTICS U.S., 2000 AND 2010 25
TABLE 6 FDA GUIDELINES FOR SELECTED PRODUCTS, 2001–2013 28
TABLE 7 ABLATION CODES 30
TABLE 8 PHYSICIAN FEE SCHEDULE CODES 31
TABLE 9 ATRIAL FIBRILLATION ABLATION, PULMONARY VEIN ISOLATION 32
TABLE 10 DIAGNOSTICS OF ELECTROPHYSIOLOGY STUDY 33
TABLE 11 GLOBAL MARKET FOR ABLATION DEVICES BY TECHNOLOGY, THROUGH
2018 ($ MILLIONS) 41
TABLE 12 GLOBAL MARKET FOR THERMAL ABLATION DEVICES BY TECHNOLOGY,
THROUGH 2018 ($ MILLIONS) 42
TABLE 13 GLOBAL MARKET FOR ELECTRICAL ABLATION THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 42
TABLE 14 GLOBAL MARKET FOR RADIATION ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 44
TABLE 15 GLOBAL MARKET FOR RADIO FREQUENCY ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 47
TABLE 16 GLOBAL MARKET FOR LIGHT/LASER ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 50
TABLE 17 GLOBAL MARKET FOR ULTRASOUND ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 51
TABLE 18 HIFU STUDIES IN KIDNEY TISSUES IN SPECIFIED COUNTRIES 52
TABLE 19 GLOBAL MARKET FOR MICROWAVE ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54
TABLE 20 GLOBAL MARKET FOR HYDROTHERMAL ABLATION TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54
TABLE 21 GLOBAL MARKET FOR NONTHERMAL ABLATION TECHNOLOGY, THROUGH
2018 ($ MILLIONS) 56
TABLE 22 GLOBAL MARKET FOR CRYOABLATION TECHNOLOGY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 57
TABLE 23 GLOBAL MARKET FOR HYDROMECHANICAL TECHNOLOGY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 58
TABLE 24 GLOBAL MARKET FOR ELECTRICAL ABLATOR BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 60
TABLE 25 GLOBAL MARKET FOR ELECTRICAL ABLATOR REVENUE BY PRODUCT,
THROUGH 2018 ($ MILLIONS) 61
TABLE 26 GLOBAL MARKET FOR RADIATION PRODUCTS BY REVENUE, THROUGH
2018 ($ MILLIONS) 62
TABLE 27 GLOBAL MARKET FOR BRACHYTHERAPY ABLATOR BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 63
TABLE 28 GLOBAL MARKET FOR HIGH-DOSE-RATE BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 63
TABLE 29 GLOBAL MARKET FOR PULSE-DOSE-RATE BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 64
TABLE 30 GLOBAL MARKET FOR PERMANENT SEED BRACHYTHERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 65
TABLE 31 GLOBAL MARKET FOR STEREOTACTIC RADIOSURGERY (SRS) AND
STEREOTACTIC RADIOTHERAPY (SRT) MARKET REVENUE BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS)
66
TABLE 32 GLOBAL MARKET FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67
TABLE 33 GLOBAL MARKET FOR INTENSITY-MODULATED RADIATION THERAPY (IMRT)
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67
TABLE 34 GLOBAL MARKET FOR STEREOTACTIC BODY RADIATION THERAPY (SBRT)
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 68
TABLE 35 GLOBAL MARKET FOR PROTON BEAM THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 69
TABLE 36 GLOBAL MARKET FOR RADIO FREQUENCY ABLATOR MARKET BY PRODUCT,
THROUGH 2018 ($ MILLIONS) 69
TABLE 37 GLOBAL MARKET FOR TEMPERATURE-CONTROLLED RADIO FREQUENCY
ABLATION DEVICES BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 70
TABLE 38 GLOBAL MARKET FOR FLUID COOLED RF ABLATION DEVICES BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71
TABLE 39 GLOBAL MARKET FOR CATHETER MANIPULATION SYSTEM DEVICES BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71
TABLE 40 GLOBAL MARKET FOR LIGHT/LASER BY PRODUCT, THROUGH 2018 ($
MILLIONS) 72
TABLE 41 GLOBAL MARKET FOR COLD LASER DEVICES BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 73
TABLE 42 GLOBAL MARKET FOR EXCIMER LASER DEVICES BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 73
TABLE 43 GLOBAL MARKET FOR ULTRASOUND ABLATION PRODUCTS, THROUGH
2018 ($ MILLIONS) 74
TABLE 44 GLOBAL MARKET FOR HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 75
TABLE 45 GLOBAL MARKET FOR MAGNETIC RESONANCE–GUIDED ULTRASOUND
(MRGUS) ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76
TABLE 46 GLOBAL MARKET FOR ULTRASONIC SURGICAL SYSTEMS BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76
TABLE 47 GLOBAL MARKET FOR EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY
PRODUCT BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 77
TABLE 48 GLOBAL MARKET FOR MICROWAVE ABLATION PRODUCT BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 78
TABLE 49 GLOBAL MARKET FOR HYDROTHERMAL ABLATION PRODUCT BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 79
TABLE 50 GLOBAL MARKET FOR CRYOABLATION PRODUCTS BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 80
TABLE 51 GLOBAL MARKET FOR ROBOTIC ABLATION BY PRODUCT, THROUGH 2018
($ MILLIONS) 83
TABLE 52 GLOBAL ABLATION MARKET BY PROCEDURE, THROUGH 2018 ($ MILLIONS) 86
TABLE 53 GLOBAL MARKET FOR AESTHETICS-SKIN REJUVENATION AND TIGHTENING
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 87
TABLE 54 GLOBAL MARKET FOR AESTHETICS-BODY SCULPTING, FAT REDUCTION
AND REDUCTION IN THE APPEARANCE OF CELLULITE ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
89
TABLE 55 GLOBAL MARKET FOR BENIGN PROSTATIC HYPERPLASIA ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 91
TABLE 56 GLOBAL MARKET FOR TRANSURETHRAL NEEDLE ABLATION PROCEDURE
BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 93
TABLE 57 GLOBAL MARKET FOR LASER- AND OTHER ENERGY-BASED ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 94
TABLE 58 GLOBAL MARKET FOR ATRIAL FIBRILLATION ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 95
TABLE 59 GLOBAL MARKET FOR CANCER ABLATION PROCEDURE BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 97
TABLE 60 GLOBAL MARKET FOR MENORRHAGIA/ENDOMETRIAL ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 98
TABLE 61 GLOBAL MARKET FOR SPINAL DECOMPRESSION AND DENERVATION
ABLATION PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 99
TABLE 62 GLOBAL MARKET FOR STRESS URINARY INCONTINENCE ABLATION
PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 101
TABLE 63 GLOBAL MARKET FOR VARICOSE VEIN ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 102
TABLE 64 GLOBAL MARKET FOR UTERINE FIBROIDS ABLATION PROCEDURE BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 103
TABLE 65 GLOBAL MARKET FOR ABLATION THERAPEUTICS, THROUGH 2018 ($
MILLIONS) 106
TABLE 66 GLOBAL MARKET FOR CANCER ABLATION THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 107
TABLE 67 GLOBAL MARKET FOR CARDIOVASCULAR ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 108
TABLE 68 GLOBAL MARKET FOR OPHTHALMOLOGY ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 109
TABLE 69 GLOBAL MARKET FOR GYNECOLOGY ABLATION THERAPY BY
GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 112
TABLE 70 GLOBAL MARKET FOR UROLOGY ABLATION THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 113
TABLE 71 GLOBAL MARKET FOR ORTHOPEDICS THERAPY BY GEOGRAPHICAL
REGION, THROUGH 2018 ($ MILLIONS) 114
TABLE 72 GLOBAL MARKET FOR OTHER THERAPY BY GEOGRAPHICAL REGION,
THROUGH 2018 ($ MILLIONS) 116
TABLE 73 LIST OF KEY PRODUCT LAUNCHES ANNOUNCED, 2010-2013 122
TABLE 74 MERGERS AND ACQUISITIONS STRATEGIES BY COMPANIES, 2010-2013 126
TABLE 75 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES,
2010-2012 129
TABLE 76 LIST OF APPROVALS AND OTHER STRATEGIES ANNOUNCED, 2010–2013 132
TABLE 77 ABLATION MARKET ESTIMATION FOR NORTH AMERICA, THROUGH 2018 ($
MILLIONS) 136
TABLE 78 ABLATION MARKET ESTIMATION FOR EUROPE, THROUGH 2018 ($
MILLIONS) 137
TABLE 79 ABLATION MARKET ESTIMATION FOR ASIA PACIFIC, THROUGH 2018 ($
MILLIONS) 138
TABLE 80 ABLATION MARKET ESTIMATION FOR ROW, THROUGH 2018 ($ MILLIONS) 140
TABLE 81 ACCURAY RECENT DEVELOPMENTS, 2010-2012 151
TABLE 82 ACCURAY FINANCIALS, 2010-2012 151
TABLE 83 ALCON RECENT DEVELOPMENT, 2012 152
TABLE 84 ALCON FINANCIALS, 2010–2012 152
TABLE 85 ANGIODYNAMICS RECENT DEVELOPMENTS, 2010-2012 154
TABLE 86 ANGIODYNAMICS FINANCIALS, 2010-2012 154
TABLE 87 ARTHROCARE RECENT DEVELOPMENTS, 2010 156
TABLE 88 ARTHROCARE CORPORATION FINANCIALS, 2010-2012 156
TABLE 89 ATRICURE RECENT DEVELOPMENTS, 2010-2011 157
TABLE 90 ATRICURE FINANCIALS, 2010-2012 158
TABLE 91 BIOSENSE WEBSTER RECENT DEVELOPMENTS, 2010-2012 159
TABLE 92 BIOSENSE WEBSTER FINANCIALS, 2010-2012 159
TABLE 93 BOSTON SCIENTIFIC CORPORATION RECENT DEVELOPMENTS, 2010-2012 161
TABLE 94 BOSTON SCIENTIFIC CORPORATION FINANCIALS, 2010-2012 161
TABLE 95 BSD MEDICALS RECENT DEVELOPMENTS, 2010-2012 162
TABLE 96 BSD MEDICALS FINANCIALS, 2010-2012 163
TABLE 97 C.R. BARD RECENT DEVELOPMENTS, 2011-2012 164
TABLE 98 C.R. BARD FINANCIALS, 2010-2012 164
TABLE 99 CONMED RECENT DEVELOPMENTS, 2010 165
TABLE 100 CONMED FINANCIALS, 2010-2012 166
TABLE 101 COVIDIEN RECENT DEVELOPMENTS, 2011-2013 167
TABLE 102 COVIDIEN FINANCIALS, 2010-2012 168
TABLE 103 ELEKTA AB RECENT DEVELOPMENTS, 2010–2013 169
TABLE 104 ELEKTA AB FINANCIALS, 2010-2012 170
TABLE 105 ENDOSENSE RECENT DEVELOPMENTS (BEFORE ACQUISITION),
2010-2011 171
TABLE 106 GALIL MEDICAL LTD RECENT DEVELOPMENTS, 2011-2012 172
TABLE 107 MEDTRONIC RECENT DEVELOPMENTS, 2010-2013 173
TABLE 108 MEDTRONIC FINANCIALS, 2010-2012 174
TABLE 109 MISONIX INC RECENT DEVELOPMENTS, 2010-2012 175
TABLE 110 MISONIX FINANCIALS, 2010-2012 176
TABLE 111 OLYMPUS RECENT DEVELOPMENTS, 2010-2012 177
TABLE 112 OLYMPUS FINANCIALS, 2010-2012 177
TABLE 113 ST. JUDE MEDICAL RECENT DEVELOPMENTS, 2010–2013 178
TABLE 114 ST. JUDE MEDICAL FINANCIALS, 2010-2012 179
TABLE 115 UROLOGIX RECENT DEVELOPMENTS, 2011-2012 180
TABLE 116 UROLOGIX FINANCIALS, 2010-2012 180
TABLE 117 VARIAN MEDICAL SYSTEMS RECENT DEVELOPMENTS, 2010-2012 181
TABLE 118 VARIAN MEDICAL SYSTEMS INC, 2010-2012 182
TABLE 119 LIST OF PATENTS: UNITED STATES, 2008-2013 184
TABLE 120 LIST OF PATENTS: EUROPE, 2008-2013 188
TABLE 121 LIST OF PATENTS: JAPAN, 2008-2013 194

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICAL
REGION, 2012-2018 ($ MILLIONS) 8
FIGURE 1 DEATHS DUE TO PROSTATE CANCER IN THE U.K., 2011 (%) 22
FIGURE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN ADULTS IN THE U.S. AGE
GROUP 45-64 YEARS, 2000 AND 2010 (%) 24
FIGURE 3 CAUSES OF VISUAL IMPAIRMENT, 2010 (%) 25
FIGURE 4 VISUAL IMPAIRMENT PER MILLION, 2010 (THOUSANDS) 26
FIGURE 5 WORLD PROJECTED MORTALITY TRENDS DUE TO CARDIOVASCULAR
DISEASES, 2008, 2015, 2030 (%) 34
FIGURE 6 U.S. CANCER DEMOGRAPHICS BY AGE AND GENDER, 2012 35
FIGURE 7 KEY COMPETITIVE STRATEGIES*, 2010-2013 (%) 119
FIGURE 8 PRODUCT LAUNCH BY COMPANY*, 2010–2013 (%) 121
FIGURE 9 MERGERS AND ACQUISITIONS BY COMPANIES*, 2010-2013 (%) 124
FIGURE 10 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES*,
2010-2013 127
FIGURE 11 APPROVALS AND OTHER STRATEGIES BY COMPANIES*, 2010-2013 (%) 131
FIGURE 12 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE AND JAPAN,
2008-2013 (%) 142
FIGURE 13 U.S. PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 143
FIGURE 14 U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 144
FIGURE 15 EUROPE PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 145
FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 146
FIGURE 17 JAPAN PATENT ANALYSIS BY TECHNOLOGY, 2008–2013 (%) 147
FIGURE 18 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 148

Read the full report:
Ablation Devices: Technologies and Global Markets

https://www.reportbuyer.com/product/2009158/Ablation-Devices-Technologies-and-Global-Markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.